Press release
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction
About this update from Organogenesis Holdings Inc.
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant maintenance of function (p
View stock analysis, news, and events for Organogenesis Holdings Inc.